Skip To Main Content

Actualización normativa

En un entorno en constante cambio como el sistema de salud, es fundamental mantenerse al día con las nuevas normativas que afectan tanto a profesionales como a pacientes. En este espacio encontrará las leyes, decretos, resoluciones y acuerdos relacionados con el sistema de salud dinámico y en evolución.

También encontrará resúmenes, análisis y todo lo relacionado con la más reciente normatividad, para comprender el posible impacto de los cambios hacia los diferentes actores del sistema.

Ordenar por
Early detection of autoimmune type 1 diabetes could reduce the risk of diabetic ketoacidosis

Early detection of autoimmune type 1 diabetes could reduce the risk of diabetic ketoacidosis

Delay in screening for autoimmune type 1 diabetes (T1D) can increase the risk of diabetic ketoacidosis (DKA) at diagnosis—a critical complication that is potentially life-threatening and may result in long-term poor glycemic control and neurological complications.1,2 By identifying autoimmune T1D early, you can significantly lower the risk of DKA at diagnosis.3,4

How should individuals with positive autoimmune T1D autoantibodies be monitored over time?

How should individuals with positive autoimmune T1D autoantibodies be monitored over time?

Individuals who screen positive for ≥1 autoimmune islet cell antibodies need periodic medical monitoring, which includes regular assessments of blood glucose and HbA1c levels. You can also educate them about symptoms of diabetes, diabetic ketoacidosis (DKA), and provide psychosocial support to prepare them for a possible clinical diagnosis for type 1 diabetes (T1D).1

Can autoimmune type 1 diabetes be detected years before symptom onset?

Can autoimmune type 1 diabetes be detected years before symptom onset?

Autoimmune type 1 diabetes (T1D) is a progressive disease in which the decline in beta cell function usually begins months or sometimes years before clinical symptoms are observed.1–3 You can identify such patients at risk of developing autoimmune T1D before clinical symptoms are noticed by you or your patient.3

Does your patient have an existing autoimmune condition? Check for autoimmune type 1 diabetes!

Does your patient have an existing autoimmune condition? Check for autoimmune type 1 diabetes!

Individuals living with other associated autoimmune diseases like celiac disease or autoimmune thyroid disease, are at an increased risk of developing autoimmune type 1 diabetes (T1D) and should be appropriately screened.1-6

Real-life stories from people living with autoimmune T1D

Real-life stories from people living with autoimmune T1D

The progression of autoimmune type 1 diabetes (T1D) is gradual, often detectable months or even years before symptoms arise.1–3 Through proactive screening, we can identify the condition well in advance.3 Meet our ambassadors living with autoimmune T1D and discover the risk factors to look out for when considering who to screen.

Early detection of autoimmune type 1 diabetes could reduce the risk of diabetic ketoacidosis

Early detection of autoimmune type 1 diabetes could reduce the risk of diabetic ketoacidosis

Delay in screening for autoimmune type 1 diabetes (T1D) can increase the risk of diabetic ketoacidosis (DKA) at diagnosis—a critical complication that is potentially life-threatening and may result in long-term poor glycemic control and neurological complications.1,2 By identifying autoimmune T1D early, you can significantly lower the risk of DKA at diagnosis.3,4

How should individuals with positive autoimmune T1D autoantibodies be monitored over time?

How should individuals with positive autoimmune T1D autoantibodies be monitored over time?

Individuals who screen positive for ≥1 autoimmune islet cell antibodies need periodic medical monitoring, which includes regular assessments of blood glucose and HbA1c levels. You can also educate them about symptoms of diabetes, diabetic ketoacidosis (DKA), and provide psychosocial support to prepare them for a possible clinical diagnosis for type 1 diabetes (T1D).1

Impiego, conservazione e stabilità dei vaccini Sanofi

Impiego, conservazione e stabilità dei vaccini Sanofi

Per saperne di più su Adacel®, Adacel®-Polio, Beyfortus®, Efluelda®, MenQuadfi®, Stamaril®, Tetravac®, Vaxelis® e VaxigripTetra®.

Adaptive Eating Behaviors in EoE

Adaptive Eating Behaviors in EoE

Adaptive Eating Behaviors in EoE

Adaptive Eating Behaviors in EoE

Pediatric EoE: Indicators for Early Diagnosis and Intervention

Pediatric EoE: Indicators for Early Diagnosis and Intervention

Pediatric EoE: Indicators for Early Diagnosis and Intervention

Pediatric EoE: Indicators for Early Diagnosis and Intervention

Material diseñado por o para Sanofi Aventis de Colombia S.A., con fines educativos y dirigido a profesionales de la salud y personal administrativo del sector salud. Es estrictamente prohibido compartir este material con terceros.

Mayor información a disposición en el Departamento Médico:

En Colombia:

Sanofi-Aventis de Colombia S.A. Transversal 23 N° 97-73 - Edificio City Business. Piso 8. Bogotá D.C. Teléfono: 621 4400 - Fax: 744 4237

infomedica.colombia@sanofi.com

En Bolivia, Centro América y Caribe:

Sanofi-Aventis de Panamá S.A. Torre Evolution, piso 26, Calle 50 y Av. Aquilino de la Guardia Obarrio- Cuidad de Panamá, República de Panamá Telf.: (507) 382-9500. infomed.pac@sanofi.com

Sitio web: http://www.sanofi.com.pa/l/pa/sp/index.jsp

 

MAT-CO-2400825 V1.0 03/2024